Lentiviral vectors in gene therapy: their current status and future potential
- PMID: 20143172
- PMCID: PMC2837622
- DOI: 10.1007/s00005-010-0063-4
Lentiviral vectors in gene therapy: their current status and future potential
Abstract
The concept of gene therapy originated in the mid twentieth century and was perceived as a revolutionary technology with the promise to cure almost any disease of which the molecular basis was understood. Since then, several gene vectors have been developed and the feasibility of gene therapy has been shown in many animal models of human disease. However, clinical efficacy could not be demonstrated until the beginning of the new century in a small-scale clinical trial curing an otherwise fatal immunodeficiency disorder in children. This first success, achieved after retroviral therapy, was later overshadowed by the occurrence of vector-related leukemia in a significant number of the treated children, demonstrating that the future success of gene therapy depends on our understanding of vector biology. This has led to the development of later-generation vectors with improved efficiency, specificity, and safety. Amongst these are HIV-1 lentivirus-based vectors (lentivectors), which are being increasingly used in basic and applied research. Human gene therapy clinical trials are currently underway using lentivectors in a wide range of human diseases. The intention of this review is to describe the main scientific steps leading to the engineering of HIV-1 lentiviral vectors and place them in the context of current human gene therapy.
Figures


Similar articles
-
Strategies for retargeted gene delivery using vectors derived from lentiviruses.Curr Gene Ther. 2004 Dec;4(4):427-43. doi: 10.2174/1566523043345995. Curr Gene Ther. 2004. PMID: 15578992 Review.
-
Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection.Curr HIV Res. 2004 Apr;2(2):185-91. doi: 10.2174/1570162043484906. Curr HIV Res. 2004. PMID: 15078182 Review.
-
Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success--a personal perspective.Hum Gene Ther. 2015 May;26(5):257-65. doi: 10.1089/hum.2015.025. Epub 2015 Apr 20. Hum Gene Ther. 2015. PMID: 25807962 Free PMC article. Review.
-
Clinical use of lentiviral vectors.Leukemia. 2018 Jul;32(7):1529-1541. doi: 10.1038/s41375-018-0106-0. Epub 2018 Mar 22. Leukemia. 2018. PMID: 29654266 Free PMC article. Review.
-
The molecular genetics of lentiviral vectors--current and future perspectives.Curr Gene Ther. 2001 Sep;1(3):237-51. doi: 10.2174/1566523013348634. Curr Gene Ther. 2001. PMID: 12109139
Cited by
-
Lentivirus-mediated short hairpin RNA interference targeting TNF-alpha in macrophages inhibits particle-induced inflammation and osteolysis in vitro and in vivo.BMC Musculoskelet Disord. 2016 Oct 18;17(1):431. doi: 10.1186/s12891-016-1290-6. BMC Musculoskelet Disord. 2016. PMID: 27756280 Free PMC article.
-
Targeting of human antigen-presenting cell subsets.J Virol. 2013 Oct;87(20):11304-8. doi: 10.1128/JVI.01498-13. Epub 2013 Jul 17. J Virol. 2013. PMID: 23864630 Free PMC article.
-
High-throughput 5' UTR engineering for enhanced protein production in non-viral gene therapies.Nat Commun. 2021 Jul 6;12(1):4138. doi: 10.1038/s41467-021-24436-7. Nat Commun. 2021. PMID: 34230498 Free PMC article.
-
Tiny Guides, Big Impact: Focus on the Opportunities and Challenges of miR-Based Treatments for ARDS.Int J Mol Sci. 2024 Feb 28;25(5):2812. doi: 10.3390/ijms25052812. Int J Mol Sci. 2024. PMID: 38474059 Free PMC article. Review.
-
Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis.Arthritis Rheum. 2011 Jan;63(1):84-95. doi: 10.1002/art.30099. Arthritis Rheum. 2011. PMID: 20967853 Free PMC article.
References
-
- Akazawa T, Ebihara T, Okuno M, Okuda Y, Shingai M, Tsujimura K, Takahashi T, Ikawa M, Okabe M, Inoue N, Okamoto-Tanaka M, Ishizaki H, Miyoshi J, Matsumoto M, Seya T. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci U S A. 2007a;104:252–7. - PMC - PubMed
-
- Akazawa T, Shingai M, Sasai M, Ebihara T, Inoue N, Matsumoto M, Seya T. Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors. FEBS Lett. 2007b;581:3334–40. - PubMed
-
- Anderson WF, Blaese RM, Culver K. The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990. Hum Gene Ther. 1990;1:331–62. - PubMed
-
- Apolonia L, Waddington SN, Fernandes C, Ward NJ, Bouma G, Blundell MP, Thrasher AJ, Collins MK, Philpott NJ. Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther. 2007;15:1947–54. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical